Seattle Genetics, Inc.

21823 - 30th Drive S.E.
98021 Bothell
USA

Contact

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.

News about Seattle Genetics

16-Sep-2020 | business & finance

Seattle Genetics and Merck & Co Announce Two Strategic Oncology Collaborations

Merck to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock

Read news

15-Sep-2011 | research and development

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

Companies to combine proprietary technologies to generate novel ADC product candidates

Read news

16-Sep-2010 | business & finance

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

Genmab A/S and Seattle Genetics, Inc. announced that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement. ...

Read news

29-Sep-2004 | business & finance

Seattle Genetics Announces Antibody-Drug Conjugate Agreement with Bayer Pharmaceuticals

Bothell. Seattle Genetics, Inc. announced that Bayer Pharmaceuticals Corporation has licensed Seattle Genetics' proprietary antibody-drug conjugate (ADC) ...

Read news

Show more news about Seattle Genetics

Get the life science industry in your inbox

Seattle Genetics, Inc.

About Seattle Genetics

News about Seattle Genetics

Seattle Genetics and Merck & Co Announce Two Strategic Oncology Collaborations

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

Seattle Genetics Announces Antibody-Drug Conjugate Agreement with Bayer Pharmaceuticals

Here you will find Seattle Genetics, Inc.

Seattle Genetics, Inc.